Caribou Biosciences(us:CRBU)

    1.77

    -1.67%

    Updated on 2024-12-23

    Open:1.83
    Close:1.77
    High:1.83
    Low:1.76
    Pre Close:1.80
    Volume:923126.00
    Amount:1.65M
    Turnover:1.02%
    Shares:90.55M
    MarketCap:160.73M
    DateTotalTotal SharesTotal RatioNewIncreasedDecreased
    2024-06-301685304408758.70%254076
    2024-03-311666643935473.56%284265
    2023-12-311536878563077.77%305345
    2023-09-301417056734879.80%265639
    2023-06-301414368919466.10%204351
    2023-03-311394485403873.14%134950
    2022-12-311404357592871.40%293648
    2022-09-301324297059370.46%134947
    dateorgNametotalratiochangeShareschangeRatio
    2024-03-31Blackrock Inc.70050627.76%-63406-0.90%
    2024-03-31Pfm Health Sciences, Lp64832707.18%25060.04%
    2024-03-31State Street Corp63473217.03%122765523.98%
    2024-03-31Avidity Partners Management Lp57853526.41%-574860-9.04%
    2024-03-31Vanguard Group Inc41107954.55%1487513.75%
    2024-03-31Point72 Asset Management, L.P.35850183.97%636421.81%
    2024-03-31Alkeon Capital Management Llc27435053.04%-370059-11.88%
    2024-03-31Elmwood Wealth Management, Inc.23642402.62%-20-0.00%
    2024-03-31Paradigm Biocapital Advisors Lp21726202.41%-751231-25.69%
    2024-03-31Dimensional Fund Advisors Lp20871212.31%73633754.51%

    About

    Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.
    Address:2929 7th Street,Suite 105

    Market Movers